S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare overall survival in newly diagnosed metastatic
prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700
versus ADT + bicalutamide.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)